Tag: STRIDE study
Cerevasc gains Health Canada approval for STRIDE trial
Cerevasc has announced the receipt of investigational testing authorisation (ITA) from Health Canada for the STRIDE trial—a clinical study evaluating the company’s eShunt system...
Cerevasc announces first patient randomised to eShunt system treatment in STRIDE...
Cerevasc has announced that the first patient has been randomised to and treated with the eShunt system in its STRIDE clinical trial—a head-to-head comparison of...
STRIDE trial assessing eShunt treatment for normal-pressure hydrocephalus gains approval in...
Cerevasc announced recently that it has received approval from Argentina's National Administration of Drugs, Food and Medical Devices (ANMAT) to initiate the STRIDE trial—a...
Cerevasc announces first enrolment in STRIDE trial evaluating eShunt system for...
Cerevasc has announced the first enrolment of a patient in the STRIDE clinical trial evaluating the company’s eShunt system in patients with normal-pressure hydrocephalus...
Cerevasc secures US$70 million financing following US FDA approval of STRIDE...
Cerevasc announced recently that it has successfully completed the initial closing of a US$70 million Series B financing, which was jointly led by Bain Capital Life...
